[Sporotrichoid cutaneous leishmaniasis in Tunisia: a clinical and histological study].
BACKGROUND
The sporotrichoid variety of cutaneous leishmaniasis is defined by the presence of dermal and hypodermal nodules along the lymphatic stream, and remote from the primary inoculation lesions. This clinical form is usually considered rare. The aim of our study was to investigate the epidemiological, clinical, histological and evolutionary particularities of sporotrichoid cutaneous leishmaniasis in the south of Tunisia.


METHODS
During a systematic study of all cases of cutaneous leishmaniasis from the south of Tunisia diagnosed in our hospital in 2002, sporotrichoid forms were diagnosed on the basis of clinical criteria. In all cases of sporotrichoid cutaneous leishmaniasis, the principal clinical characters were systematically specified. Cutaneous biopsies of subcutaneous nodules were performed in six cases.


RESULTS
Of 102 patients with cutaneous leishmaniasis, 19 presented sporotrichoid cutaneous leishmaniasis, that is, a frequency of 19%. Between two and 20 painless subcutaneous nodules were arranged in linear strings on the upper leg in 79% of cases. Time to appearance varied between 12 days and one year after the primary lesions. Fourteen appeared without any preliminary treatment for cutaneous leishmaniasis and five appeared after Glucantime infiltration in the primary lesions. Biopsies of the nodules showed an inflammatory infiltrate composed of lymphocytes and histiocytes. This infiltrate was particularly dense and rich in plasmocytes at the level of the deep dermis. The biopsies were deep enough to involve the hypoderm in one case and the same type of infiltrate was noted at the level of interlobular septa. A small number amastigotes was seen in one deep biopsy sample. Outcome was favourable in all cases under treatment.


CONCLUSIONS
Sporotrichoid cutaneous leishmaniasis appears to be common in the south of Tunisia, were cutaneous leishmaniasis is dominant because of Leishmania major. It is not associated with a poor prognosis.
Masmoudi
A
A
Service de dermatologie et de vénéréologie, CHU Hédi-Chaker, 3029 Sfax, Tunisie.
Ayadi
N
N
Khabir
A
A
Bouzid
L
L
Bouassida
S
S
Meziou
T J
TJ
Akrout
F
F
Zahaf
A
A
Boudawara
T
T
Turki
H
H
D000328:Adult; D000368:Aged; D000890:Anti-Infective Agents / Q000627:therapeutic use; D000981:Antiprotozoal Agents / Q000627:therapeutic use; D005260:Female; D006644:Histiocytes / Q000473:pathology; D006801:Humans; D007868:Leg Dermatoses / Q000188:drug therapy / Q000473:pathology*; D016773:Leishmaniasis, Cutaneous / Q000188:drug therapy / Q000473:pathology*; D008214:Lymphocytes / Q000473:pathology; D008297:Male; D008536:Meglumine / Q000627:therapeutic use; D000077485:Meglumine Antimoniate; D008795:Metronidazole / Q000627:therapeutic use; D008875:Middle Aged; D009942:Organometallic Compounds / Q000627:therapeutic use; D011446:Prospective Studies; D013174:Sporotrichosis / Q000188:drug therapy / Q000473:pathology*; D014416:Tunisia
D000890:Anti-Infective Agents; D000981:Antiprotozoal Agents; D009942:Organometallic Compounds; D008795:Metronidazole; D008536:Meglumine; D000077485:Meglumine Antimoniate